GLPwatch
Papers (10410)
Page 134 of 174, ranked by citation count.
- Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.
- Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
- Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
- Drug updates and approvals: 2015 in review.
- [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
- RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.
- The Effectiveness of Semaglutide on a Composite Endpoint of Glycemic Control and Weight Reduction and Its Effect on Lipid Profile Among Obese Type 2 Diabetes Patients.
- Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.
- Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
- Exendin-4, a glucagon-like peptide receptor agonist, facilitates osteoblast differentiation via connexin43.
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.
- From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.
- Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Incretin-based approaches for type 2 diabetes therapy: effects on circulating cytokines and adipocyte's secretome.
- Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.
- Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.
- Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
- Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
- Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.
- Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.
- Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.
- Structural stability-chromatographic retention relationship on exenatide diastereomer separation.
- Exenatide implant therapy in diabetes.
- Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.
- Rhabdomyolysis triggered by initiation of tirzepatide.
- Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
- Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Neurological outcomes of antidiabetic therapy: What the neurologist should know.
- Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
- Semaglutide and risk of suicidal ideations.
- Accuracy of dosage volume for halfway doses in the Victoza Pen.
- Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail.
- Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.
- [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
- Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
- A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.
- GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
- Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.
- Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
- Tirzepatide-New Evidence for the Treatment of Obesity From China.
- Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
- Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health.
- A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice.
- Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
- Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively.
- A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach.
- [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
- Glucagon-like peptide-1 agonists.
- Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
- Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
- Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
- New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.
- Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.
- Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
- GLP1 receptor agonism alters growth and therapeutic response in prostate cancer.